UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
24.12
+0.35 (1.47%)
At close: Apr 28, 2026, 4:00 PM EDT
24.29
+0.17 (0.70%)
Pre-market: Apr 29, 2026, 8:13 AM EDT
UroGen Pharma Employees
UroGen Pharma had 291 employees as of December 31, 2025. The number of employees increased by 56 or 23.83% compared to the previous year.
Employees
291
Change (1Y)
56
Growth (1Y)
23.83%
Revenue / Employee
$377,278
Profits / Employee
-$527,471
Market Cap
1.17B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| AbCellera Biologics | 562 |
| Pharming Group | 407 |
| uniQure | 221 |
| EyePoint | 214 |
| Zenas BioPharma | 167 |
| Olema Pharmaceuticals | 131 |
| MoonLake Immunotherapeutics | 130 |
| Septerna | 130 |
URGN News
- 21 days ago - UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer - GlobeNewsWire
- 4 weeks ago - Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI - GlobeNewsWire
- 7 weeks ago - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - UroGen Pharma Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - UroGen Pharma Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors - GlobeNewsWire
- 2 months ago - ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC - GlobeNewsWire